FDA label
What is Nivestym used for?
Nivestym contains filgrastim. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Nivestym lists 5 uses: Patients with Cancer Receiving Myelosuppressive Chemotherapy; Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy; Patients with Cancer Undergoing Bone Marrow Transplantation; Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy; and 1 more.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Nivestym?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Nivestym, injection, solution
Indications and Usage, quoted from the label by Pfizer Laboratories Div Pfizer Inc (BLA761080). Cross-references to other label sections are left out.
Patients with Cancer Receiving Myelosuppressive Chemotherapy
NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
Patients with Cancer Undergoing Bone Marrow Transplantation
NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy
NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
Patients with Severe Chronic Neutropenia
NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
Source: DailyMed label, set id d23ab39c-b6ec-41cf-a529-9dd2852c9d9a, version 18, effective August 12, 2025. NDC 0069-0291, one of 4 listings for this product.
Questions
What is Nivestym used for?
The FDA label for Nivestym lists 5 uses: Patients with Cancer Receiving Myelosuppressive Chemotherapy; Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy; Patients with Cancer Undergoing Bone Marrow Transplantation; Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy; and 1 more.
What drug class is Nivestym?
FDA lists filgrastim in the Leukocyte Growth Factor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.